Biomedical, Clinical & Life Sciences

M. Dodson

UArizona is allowed a maximum of one nomination per grant cycle to one of the Pathway Program Award types: Initiator or Accelerator. Institutions may not submit nominations in multiple award types in a single grant cycle.

To accelerate the research needed to stop this deadly disease, the American Diabetes Association’s bold transformational initiative, Pathway to Stop Diabetes, is inspiring a new generation of diabetes researchers.

Eligibility for Accelerator Awards (ACC)
Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for (regardless of outcome), or received, an R01/U01 renewal or a second R01/U01 award. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.

Amount Upper: $1,625,000USD
Award Term: Up to 5 years
Maximum Funding: $325,000/year

Eligibility for Initiator Award (INI)
Eligible applicants must currently be in research training positions (post-doctoral fellow, research fellowship) and have no more than seven years of research training following terminal doctoral degree. Applicants cannot concurrently hold an NIH K99/R00 grant. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.

Amount Upper: $1,625,000USD
Award Term: Up to 7 year
Maximum Funding: Up to $100,000/year in Phase 1, Up to $325,000/year in Phase 2

May 24, 2022 update: The program for 2022 has been discontinued by the external sponsor. RDS has concluded the internal competition. Contact RDS with questions

UArizona may submit one nomination.

The mission of the Foundation is to support early stage investigators engaged in basic biomedical research that has the potential to significantly advance the understanding, diagnosis or treatment of disease. Any domestic biomedical institution, whether solely research or educational, is invited to submit one candidate for the Mallinckrodt Board's consideration.

Each institution is allowed to submit one proposal. Applicants should be in the first to fourth year of their tenure track faculty position and not have current R01 funding. Grants are usually $60,000 and funding commences on October 1. No indirect costs are allowed. Salary is acceptable.

S. Doroudgar

UArizona may submit one proposal.

The Harold S. Geneen Charitable Trust Awards Program for Coronary Heart Disease Research supports research in the area of the prevention of coronary heart disease or circulatory failure, and improving care for these patients. The Program focuses on basic and translational scientific research. Clinical studies are currently ineligible. Each invited institution may submit a single application from a full-time faculty member. United States citizenship is not required. Junior faculty and those with less than $500,000 in direct costs funding at the time of application are encouraged to apply.

Ticket #1: R. van der Pijl
Ticket #2: Available

UArizona may submit two applications.

The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce.

No applicants // Limit: 1 // Tickets Available: 1 

While HRSA-22-124 is a stand-alone limited submission, UArizona may only submit one application to HRSA-22-122, HRSA-22-124, or HRSA-22-122. Therefore, submissions to these funding opportunities are Institutionally Coordinated and only the selected PI is eligible to submit. Please Contact Bekah Coskun, Associate, Biomedical, Clinical & Health Sciences, RDS, with any questions.

No applicants // Limit: 1 // Tickets Available: 1 

While HRSA-22-117 is not a limited submission, UArizona may only submit one application to HRSA-22-122, HRSA-22-124, or HRSA-22-122. Therefore, submissions to these funding opportunities are Institutionally Coordinated and only the selected PI is eligible to submit. Please Contact Bekah Coskun, Associate, Biomedical, Clinical & Health Sciences, RDS, with any questions.

K. Ernst

While HRSA-22-122 is not a limited submission, UArizona may only submit one application to HRSA-22-122, HRSA-22-124, or HRSA-22-122. Therefore, submissions to these funding opportunities are Institutionally Coordinated and only the selected PI is eligible to submit. Please Contact Bekah Coşkun, Associate, Biomedical, Clinical & Health Sciences, RDS, with any questions.

J. Armin

Institutionally Coordinated - RDS // No applicants // Limit: 1 // Tickets Available: 1 

The goal of the Bridges to the Baccalaureate Research Training Program is to provide structured activities to prepare a diverse cohort of research-oriented students to transfer from associate degree-granting institutions to baccalaureate degree-granting institutions and complete a baccalaureate degree in disciplines related to the biomedical sciences. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise.

No applicants // Limit: 1 // Tickets Available: 1 

The National Cancer Institute (NCI) invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for cancer research career continuity